Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial

被引：0
|
作者：
George, D. J. [1 ]
Pantuck, A. J. [2 ]
Figlin, R. [3 ]
Escudier, B. [4 ]
Halabi, S. [5 ]
Casey, M. [6 ]
Lin, X. [7 ]
Serfass, L. [8 ]
Frean, M. J. Lechuga [9 ]
Ravaud, A. [10 ]
机构：
[1] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[2] Ronald Reagan UCLA Med Ctr, Dept Urol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Med Hematol Oncol, Los Angeles, CA 90048 USA
[4] Gustave Roussy Inst Cancerol, Dept Med Oncol, Villejuif, France
[5] Duke Univ, Biostat & Bioinformat, Durham, NC USA
[6] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[7] Pfizer Inc, Oncol, La Jolla, CA USA
[8] Pfizer, Med, Paris, France
[9] Pfizer, Oncol, Milan, Italy
[10] Hop St Andre, CHU Bordeaux, Dept Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881P
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [1] S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).
    George, Daniel J.
    Pantuck, Allan J.
    Motzer, Robert J.
    Ravaud, Alain
    Escudier, Bernard
    Staehler, Michael D.
    Serfass, Lucile
    Krishnaswami, Sriram
    Casey, Michelle
    Lechuga, Mariajose
    Koch, Gary
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC).
    Harshman, Lauren Christine
    Xie, Wanling
    Moreira, Raphael Brandao
    Gustavo, Ruiz
    Sweeney, Christopher
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Kliment, J.
    Pantuck, A. J.
    Patel, A.
    Deannuntis, L.
    Bhattacharyya, H.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Patard, J-J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.
    Ravaud, Alain
    George, Daniel J.
    Motzer, Robert J.
    Pantuck, Allan J.
    Staehler, Michael D.
    Serfass, Lucile
    Krishnaswami, Sriram
    Casey, Michelle
    DeAnnuntis, Liza L.
    Lechuga, Mariajose
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
    Patel, Anup
    Ravaud, Alain
    Motzer, Robert J.
    Pantuck, Allan J.
    Staehler, Michael
    Escudier, Bernard
    Martini, Jean-Francois
    Lechuga, Mariajose
    Lin, Xun
    George, Daniel J.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4863 - 4868
  • [6] Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.
    Patel, Anup
    Ravaud, Alain
    Motzer, Robert J.
    Pantuck, Allan J.
    Staehler, Michael D.
    Escudier, Bernard
    Martini, Jean-Francois
    Krishnaswami, Sriram
    Casey, Michelle
    Lechuga, Mariajose
    Lin, Xun
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.
    Dabestani, Saeed
    Beisland, Christian
    Stewart, Grant
    Capitanio, Umberto
    Jarvinen, Petrus
    Nisen, Harry
    Bensalah, Karim
    Gudmundsson, Eirikur
    Lam, Thomas B.
    Marconi, Lorenzo
    Fernandez-Pello, Sergio
    Monagas, Serenella
    Powles, Thomas
    Meijer, Richard Paul
    Volpe, Alessandro
    Staehler, Michael D.
    Ljungberg, Borje
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
    George, Daniel J.
    Martini, Jean-Francois
    Staehler, Michael
    Motzer, Robert J.
    Magheli, Ahmed
    Escudier, Bernard
    Gerletti, Paola
    Li, Sherry
    Casey, Michelle
    Laguerre, Brigitte
    Pandha, Hardev S.
    Pantuck, Allan J.
    Patel, Anup
    Lechuga, Maria J.
    Ravaud, Alain
    CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1554 - 1561
  • [9] Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.
    Haas, Naomi B.
    Song, Yan
    Rogerio, Jaqueline Willemann
    Zhang, Su
    Adejoro, Oluwakayode
    Carley, Christopher
    Zhu, Jingjing
    Bhattacharya, Rituparna
    Signorovitch, James
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS)
    Raut, C.
    Miceli, R.
    Strauss, D.
    Swallow, C.
    Hohenberger, P.
    Van Coevorden, F.
    Rutkowski, P.
    Fiore, M.
    Callegaro, D.
    Casali, P.
    Haas, R.
    Hayes, A.
    Honore, C.
    Cannell, A.
    Jakob, J.
    Szacht, M.
    Fairweather, M.
    Pollock, R.
    Bonvalot, S.
    Gronchi, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S689 - S690
12345